Hingorani, Pooja

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 206

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 197

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 127

Lifestyle behavior interventions delivered using technology in childhood, adolescent, and young adult cancer survivors: a systematic review

Kopp, L. M., Gastelum, Z., Guerrero, C. H., Howe, C. L., Hingorani, P., & Hingle, M. (2017) · Pediatric Blood & Cancer

Childhood Cancer Survivors' Quality of LifeCancer survivorship and care

Cited by 56

ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

Hingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., Teicher, B., Erickson, S., Gatto, G., Smith, M. A., et al. (2021) · Molecular Cancer Therapeutics

Sarcoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 41

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Wang, Y., Tian, X., Zhang, W., Zhang, Z., Lazcano, R., Hingorani, P., Roth, M. E., Gill, J. D., Harrison, D. J., Xu, Z., et al. (2022) · Molecular Cancer Therapeutics

Sarcoma Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 37

Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium

Hingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 28

Abstract LB-217: Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)

Hingorani, P., Zhang, W., Kurmasheva, R., Zhang, Z., Wang, Y., Xu, Z., Roth, M., Gill, J., Harrison, D., Erickson, S., et al. (2020) · Cancer Research

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 6